BL_genes.md
... ...
@@ -11,7 +11,7 @@ link-citations: true
11 11
12 12
## Tier 1 BL genes
13 13
14
-### *28 total*
14
+### *27 total*
15 15
16 16
|Gene|Summary| First BL study | Other entities | QC result |
17 17
|:-:|:-:|:-:|:-|:-|
... ...
@@ -21,7 +21,6 @@ link-citations: true
21 21
|[CCND3](CCND3)|Tier 1 GE[@richterRecurrentMutationID32012a], FE[@schmitzBurkittLymphomaPathogenesis2012]|[Richter et al](papers/richterRecurrentMutationID32012a)|[@deschGenotypingCirculatingTumor2020; @jalladesExomeSequencingIdentifies2017; @morinFrequentMutationHistonemodifying2011]||
22 22
|[CHD8](CHD8)|Tier 1 GE[@grandeGenomewideDiscoverySomatic2019]|[Grande et al](papers/grandeGenomewideDiscoverySomatic2019)|||
23 23
|[DDX3X](DDX3X)|Tier 1 GE[@schmitzBurkittLymphomaPathogenesis2012], FE[@gongSequentialInverseDysregulation2021], CE[@kizhakeyilDDX3XLossAdverse2021]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|[@mottokIntegrativeGenomicAnalysis2019b; @reddyGeneticFunctionalDrivers2017]||
24
-|[EPPK1](EPPK1)|Tier 1 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|||
25 24
|[FBXO11](FBXO11)|Tier 1 GE[@richterRecurrentMutationID32012a], FE[@schneiderFBXO11InactivationLeads2016b]|[Richter et al](papers/richterRecurrentMutationID32012a)|[@hubschmannMutationalMechanismsShaping2021b; @parryWholeExomeSequencing2013]||
26 25
|[FOXO1](FOXO1)|Tier 1 GE[@schmitzBurkittLymphomaPathogenesis2012], FE[@trinhAnalysisFOXO1Mutations], CE[@trinhAnalysisFOXO1Mutations]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|[@dunsCharacterizationDLBCLPMBL2021b; @morinFrequentMutationHistonemodifying2011]||
27 26
|[GNA13](GNA13)|Tier 1 GE[@loveGeneticLandscapeMutations2012], FE[@muppidiLossSignalingGa132014b]|[Love et al](papers/loveGeneticLandscapeMutations2012)|[@morinFrequentMutationHistonemodifying2011; @reichelFlowSortingExome2015a]||
... ...
@@ -46,7 +45,7 @@ link-citations: true
46 45
47 46
## Tier 2 BL genes
48 47
49
-### *76 total*
48
+### *77 total*
50 49
51 50
|Gene|Summary| First BL study | Other entities | QC result |
52 51
|:-:|:-:|:-:|:-|:-|
... ...
@@ -77,6 +76,7 @@ link-citations: true
77 76
|[EHD1](EHD1)|Tier 2 GE[@thomasGeneticSubgroupsInform2023]|[Thomas et al](papers/thomasGeneticSubgroupsInform2023)|||
78 77
|[EIF4A1](EIF4A1)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|||
79 78
|[ELP2](ELP2)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
79
+|[EPPK1](EPPK1)|Tier 2 GE[@paneaWholeGenomeLandscape2019]|[Panea et al](papers/paneaWholeGenomeLandscape2019)|||
80 80
|[ERAP1](ERAP1)|Tier 2 GE[@burkhardtClinicalRelevanceMolecular2022b]|[Burkhardt et al](papers/burkhardtClinicalRelevanceMolecular2022b)|||
81 81
|[EXOSC6](EXOSC6)|Tier 2 GE[@schmitzBurkittLymphomaPathogenesis2012]|[Schmitz et al](papers/schmitzBurkittLymphomaPathogenesis2012)|||
82 82
|[EZH2](EZH2)|Tier 2 GE[@loveGeneticLandscapeMutations2012], FE[@yapSomaticMutationsEZH22011b]|[Love et al](papers/loveGeneticLandscapeMutations2012)|[@morinSomaticMutationsAltering2010a; @mottokIntegrativeGenomicAnalysis2019b]|PASS|